Terns Pharmaceuticals stock jumps 10% as JPM conference puts TERN-701 back on the map

Terns Pharmaceuticals shares jumped over 10% Wednesday, fueled by the company’s newest conference update on its lead cancer drug. By midday, the stock had risen 10.4% to $38.03, after trading in a range from $34.05 to $38.35.